CN101501060B - 用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽 - Google Patents

用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽 Download PDF

Info

Publication number
CN101501060B
CN101501060B CN2007800292667A CN200780029266A CN101501060B CN 101501060 B CN101501060 B CN 101501060B CN 2007800292667 A CN2007800292667 A CN 2007800292667A CN 200780029266 A CN200780029266 A CN 200780029266A CN 101501060 B CN101501060 B CN 101501060B
Authority
CN
China
Prior art keywords
arg
res
mod
peptide
xaa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN2007800292667A
Other languages
English (en)
Chinese (zh)
Other versions
CN101501060A (zh
Inventor
玛丽亚·温琴扎·卡列罗
马里奥·德罗萨
温琴佐·帕沃纳
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clyde Pharmaceutical Co
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CN101501060A publication Critical patent/CN101501060A/zh
Application granted granted Critical
Publication of CN101501060B publication Critical patent/CN101501060B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1019—Tetrapeptides with the first amino acid being basic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K4/00—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
    • C07K4/12—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Transplantation (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN2007800292667A 2006-08-09 2007-07-19 用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽 Expired - Fee Related CN101501060B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT001607A ITMI20061607A1 (it) 2006-08-09 2006-08-09 Peptidi con attivita farmacologica
ITMI2006A001607 2006-08-09
PCT/EP2007/006424 WO2008017372A1 (fr) 2006-08-09 2007-07-19 Peptides ayant une activité pharmacologique pour le traitement de troubles associés à la migration de cellules altérées, tels que le cancer

Publications (2)

Publication Number Publication Date
CN101501060A CN101501060A (zh) 2009-08-05
CN101501060B true CN101501060B (zh) 2012-11-07

Family

ID=38776401

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2007800292667A Expired - Fee Related CN101501060B (zh) 2006-08-09 2007-07-19 用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽

Country Status (22)

Country Link
US (1) US8354374B2 (fr)
EP (3) EP2049562B1 (fr)
JP (1) JP5384342B2 (fr)
KR (1) KR101464576B1 (fr)
CN (1) CN101501060B (fr)
AT (1) ATE544775T1 (fr)
AU (1) AU2007283150B2 (fr)
BR (1) BRPI0715407A2 (fr)
CA (1) CA2660183C (fr)
CY (2) CY1113941T1 (fr)
DK (2) DK2213680T3 (fr)
ES (2) ES2404052T3 (fr)
HR (1) HRP20130331T1 (fr)
IL (1) IL196929A (fr)
IT (1) ITMI20061607A1 (fr)
ME (1) ME02425B (fr)
MX (1) MX2009001452A (fr)
PL (2) PL2213680T3 (fr)
PT (2) PT2049562E (fr)
RS (1) RS52786B (fr)
SI (2) SI2049562T1 (fr)
WO (1) WO2008017372A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
KR20120118008A (ko) 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 ｃ 바이러스 억제제
WO2013044500A1 (fr) * 2011-09-30 2013-04-04 Cheng Yun Applications d'un peptide immunogène du virus de l'hépatite c ou de ses dérivés pour la préparation prophylactique ou thérapeutique de l'arthrite
JP6228187B2 (ja) 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
AU2013295035B2 (en) 2012-07-23 2017-08-03 Zealand Pharma A/S Glucagon analogues
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
US9988429B2 (en) * 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
WO2015055801A1 (fr) 2013-10-17 2015-04-23 Zealand Pharma A/S Analogues acylés du glucagon
MX2016005556A (es) 2013-11-06 2016-07-15 Zealand Pharma As Compuestos agonistas duales de gip-glp-1 y procedimientos.
AU2014345570B2 (en) 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
US10253078B2 (en) 2014-10-29 2019-04-09 Zealand Pharma A/S GIP agonist compounds and methods
US10336802B2 (en) 2015-04-16 2019-07-02 Zealand Pharma A/S Acylated glucagon analogue
ITUB20169937A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche e loro uso per il trattamento della retinite pigmentosa
ITUB20169928A1 (it) * 2016-01-12 2017-07-12 Medical And Biotechnological Services In Sigla M B S Srl Formulazioni farmaceutiche per il trattamento del diabete
EP3231811A1 (fr) 2016-04-11 2017-10-18 Istituto Nazionale Tumori Irccs "Fondazione G. Pascale" Inhibiteurs peptidiques rétro-inverso de la migration cellulaire, matrice extracellulaire et invasion endothéliale par des cellules tumorales
US20190145962A1 (en) * 2016-04-14 2019-05-16 Tao Health Life Pharma Co., Ltd. Peptide for inhibiting binding of amylospheroids (aspd), and evaluation and screening method
CN112789031B (zh) 2018-09-28 2023-03-24 胡桃钳医疗公司 用于核酸递送的包含脂化的阳离子肽化合物的脂质纳米颗粒制剂
IT202200007754A1 (it) 2022-04-19 2023-10-19 Iridea S R L Nuovi composti con attivita’ farmacologica

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES501583A0 (es) * 1981-04-23 1982-02-16 Jorba Puigsubira Jose Ma Un procedimiento para la preparacion de oligopeptidos lisi- na-triptofano y de sus derivados y sales fisiologicamente aprovechables
CA2094785A1 (fr) * 1992-05-08 1993-11-09 Jean Gariepy Peptide chelatant le metal
US20030009022A1 (en) 1993-03-31 2003-01-09 Cadus Pharmaceutical Corporation Methods and compositions for identifying receptor effectors
US6046167A (en) 1998-03-25 2000-04-04 University Of Cincinnati Peptide YY analogs
US6388054B1 (en) 1998-08-20 2002-05-14 John M. Stewart Anti-cancer compounds
JP4486187B2 (ja) 1998-10-27 2010-06-23 武田薬品工業株式会社 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド
DK174549B1 (da) * 2000-02-01 2003-05-26 Raaco Internat A S Indretning til optagelse og fastholdelse af værktøjer
WO2001071342A2 (fr) * 2000-03-23 2001-09-27 Novartis Ag Composes organiques
US20050240008A1 (en) 2000-03-30 2005-10-27 Tetsuya Ohtaki Novel protein, dna thereof and process for producing the same
EP1322954A4 (fr) 2000-09-13 2005-08-03 Eleanor Roosevelt Inst Procede de traitement de la resistance a l'insuline dans l'obesite et le diabete
US7737256B2 (en) * 2001-01-25 2010-06-15 Fondazione Centro San Raffaele Del Monte Tabor Antibody against uPA/uPAR
US6815426B2 (en) * 2001-02-16 2004-11-09 E. I. Du Pont De Nemours And Company Angiogenesis-inhibitory tripeptides, compositions and their methods of use
WO2002085399A1 (fr) 2001-04-20 2002-10-31 Takeda Chemical Industries, Ltd. Preparations contenant un peptide
KR100803092B1 (ko) 2002-01-29 2008-02-18 주식회사 포스코 면역 조절 펩타이드
WO2004085455A1 (fr) 2003-03-24 2004-10-07 The University Of Hong Kong Essai de diagnostic du virus humain causant le syndrome respiratoire aigu severe (sars)
AR049938A1 (es) 2004-06-25 2006-09-13 Takeda Pharmaceutical Derivados de metastina y utilizacion de los mismos
EP1765378B1 (fr) 2004-07-12 2014-04-16 Medical Research Fund of Tel Aviv Sourasky Medical Center Agents capable de reguler a la baisse un hif-1g(a) dependant de msf-a et utilisation de ceux-ci pour traiter un cancer
JP5189082B2 (ja) * 2006-05-25 2013-04-24 バイエル・ファルマ・アクチェンゲゼルシャフト 二量体分子複合体

Also Published As

Publication number Publication date
EP2049562B1 (fr) 2013-02-27
SI2213680T1 (sl) 2013-06-28
HK1136304A1 (en) 2010-06-25
AU2007283150B2 (en) 2012-11-29
PL2049562T3 (pl) 2013-07-31
BRPI0715407A2 (pt) 2013-07-02
HRP20130331T1 (hr) 2013-05-31
ES2404052T3 (es) 2013-05-23
AU2007283150A1 (en) 2008-02-14
DK2213680T3 (da) 2013-05-06
SI2049562T1 (sl) 2013-06-28
PT2213680E (pt) 2013-05-10
KR101464576B1 (ko) 2014-12-04
ATE544775T1 (de) 2012-02-15
CY1114014T1 (el) 2016-07-27
EP2213680B1 (fr) 2013-03-20
EP2230245A1 (fr) 2010-09-22
CN101501060A (zh) 2009-08-05
ITMI20061607A1 (it) 2008-02-10
US8354374B2 (en) 2013-01-15
KR20090051041A (ko) 2009-05-20
PL2213680T3 (pl) 2013-08-30
US20110230397A1 (en) 2011-09-22
PT2049562E (pt) 2013-04-24
IL196929A (en) 2016-02-29
WO2008017372A1 (fr) 2008-02-14
MX2009001452A (es) 2009-04-08
CA2660183C (fr) 2016-09-27
JP2010500298A (ja) 2010-01-07
RS52786B (sr) 2013-10-31
EP2230245B1 (fr) 2012-02-08
ME02425B (fr) 2016-09-20
CA2660183A1 (fr) 2008-02-14
DK2049562T3 (da) 2013-04-15
CY1113941T1 (el) 2016-07-27
JP5384342B2 (ja) 2014-01-08
EP2049562A1 (fr) 2009-04-22
IL196929A0 (en) 2009-11-18
EP2213680A1 (fr) 2010-08-04
ES2406090T3 (es) 2013-06-05

Similar Documents

Publication Publication Date Title
CN101501060B (zh) 用于治疗与异常细胞迁移相关的诸如癌症等疾病的具有药学活性的肽
CN101678213B (zh) 环肽cxcr4拮抗剂
CA2400410C (fr) Composes antimicrobiens et preparations
AU725164B2 (en) Novel dolastatin derivatives, their preparation and use
US20240033318A1 (en) Peptidyl inhibitors of calcineurin-nfat interaction
EP0478101B1 (fr) Utilisation thérapeutique des peptides ayant une activité de type thrombospondine
EP3559020B1 (fr) Nouveaux peptides agrafés et leurs utilisations
CN101072589A (zh) 增强细胞摄取活性的共轭分子复合物
CA2405724C (fr) Analogues de la substance p destines au traitement du cancer
AU671118B2 (en) Tachykinin antagonist tricyclic compounds, preparation of same and pharmaceutical compositions containing such compounds
US6596692B1 (en) Substance P analogs for the treatment of cancer
CN113896766A (zh) 一种新的抗肿瘤环肽类活性分子、制备方法及应用
CN113861269A (zh) Dr8多肽类似物及其制备方法和应用
JP3939354B2 (ja) 抗腫瘍性ペプチド
HK1136304B (en) Peptides having pharmacological activity for treating disorders associated with altered cell migration, such as cancer
BR112020009113A2 (pt) peptidomiméticos de grampo beta
EA051613B1 (ru) Ингибиторы фактора с3 системы комплемента и варианты их применения в медицине

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1136304

Country of ref document: HK

ASS Succession or assignment of patent right

Owner name: FAMA FELIX LTD.

Free format text: FORMER OWNER: CARRIERO MARIA VINCENZA

Effective date: 20120606

Free format text: FORMER OWNER: DE ROSA MARIO PAVONE VINCENZO

Effective date: 20120606

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20120606

Address after: Italy Napoli

Applicant after: Carriero Maria Vincenza

Address before: Italy Napoli

Applicant before: Carriero Maria Vincenza

Co-applicant before: De Rosa Mario

Co-applicant before: Pavone Vincenzo

C14 Grant of patent or utility model
GR01 Patent grant
REG Reference to a national code

Ref country code: HK

Ref legal event code: GR

Ref document number: 1136304

Country of ref document: HK

TR01 Transfer of patent right
TR01 Transfer of patent right

Effective date of registration: 20170608

Address after: Swiss Frey Enver

Patentee after: Clyde pharmaceutical company

Address before: Italy Napoli

Patentee before: Carriero Maria Vincenza

CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20121107

Termination date: 20200719

CF01 Termination of patent right due to non-payment of annual fee